High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma

Carcinogenesis

Volumn 35, Issue 7, 2014, Pages

  Ahmed, Maqbool ^a   Hussain, Azhar R ^a   Bavi, Prashant ^a   Ahmed, Saeeda O ^a   AlSobhi, Saif S ^a   Al Dayel, Fouad ^a   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIN D1; DIMETHYL SULFOXIDE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B; TORIN 2; UNCLASSIFIED DRUG; 9 (6 AMINOPYRIDIN 3 YL) 1 (3 (TRIFLUOROMETHYL)PHENYL)BENZO(H)(1,6)NAPHTHYRIDIN 2(1H) ONE; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO(H)(1,6)NAPHTHYRIDIN-2(1H)-ONE; EIF4EBP1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; NAPHTHYRIDINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER MODEL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA TRANSLATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; COHORT ANALYSIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MITOCHONDRION; NUDE MOUSE; PAPILLARY CARCINOMA; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; THYROID TUMOR; TISSUE MICROARRAY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA, FOLLICULAR; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CASPASES; CELL CYCLE; CELL PROLIFERATION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; MIDDLE AGED; MITOCHONDRIA; MULTIPROTEIN COMPLEXES; NAPHTHYRIDINES; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903949127     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu051     Document Type: Article

References (51)

1. Ito, Y. et al. (2013) Increasing incidence of thyroid cancer: controversies explored. Nat. Rev. Endocrinol., 9, 178-184.
2. Nixon, I.J. et al. (2012) Changing trends in well differentiated thyroid carcinoma over eight decades. Int. J. Surg., 10, 618-623.
3. Davies, L. et al. (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 295, 2164-2167.
4. Antonelli, A. et al. (2011) New targeted therapies for thyroid cancer. Curr. Genomics, 12, 626-631.
5. Hussain, F. et al. (2013) Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000-2010. Hematol. Oncol. Stem Cell Ther., 6, 58-64.
6. Loh, K.C. et al. (1997) Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab., 82, 3553-3562.
7. Lang, B.H. et al. (2012) Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann. Surg. Oncol., 19, 1257-1263.
8. Schlumberger, M. et al. (2012) Approach to the patient with advanced differentiated thyroid cancer. Eur. J. Endocrinol., 166, 5-11.
9. Grande, E. et al. (2012) Thyroid cancer: molecular aspects and new therapeutic strategies. J. Thyroid Res., 2012, 847108.
10. Beauchamp, E.M. et al. (2013) The evolution of the TOR pathway and its role in cancer. Oncogene, 32, 3923-3932.
11. Nam, H.Y. et al. (2013) Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition. Cancer Res., 73, 4267-4277.
12. Zoncu, R. et al. (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol., 12, 21-35.
13. Laplante, M. et al. (2012) mTOR signaling in growth control and disease. Cell, 149, 274-293.
14. Foster, K.G. et al. (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem., 285, 14071-14077.
15. Foster, K.G. et al. (2010) Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J. Biol. Chem., 285, 80-94.
16. Nawroth, R. et al. (2011) S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One, 6, e27509.
17. Zhou, H. et al. (2011) Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci., 12, 30-42.
18. Zhou, H. et al. (2010) The complexes of mammalian target of rapamycin. Curr. Protein Pept. Sci., 11, 409-424.
19. Zhang, H. et al. (2013) A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One, 8, e54918.
20. Wolin, E.M. (2013) PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett., 335, 1-8.
21. Uddin, S. et al. (2006) Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood, 108, 4178-4186.
22. Hussain, A.R. et al. (2012) Cross-talk between NFkB and the PI3-kinase/ AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One, 7, e39945.
23. Uddin, S. et al. (2010) Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int. J. Cancer, 126, 382-394.
24. Anandappa, G. et al. (2010) Everolimus - a new approach in the treatment of renal cell carcinoma. Cancer Manag. Res., 2, 61-70.
25. Lauring, J. et al. (2013) The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J. Natl. Compr. Canc. Netw., 11, 670-678.
26. Motzer, R.J. et al. (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 116, 4256-4265.
27. Motzer, R.J. et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372, 449-456.
28. Rini, B.I. et al. (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol., 10, 992-1000.
29. Uddin, S. et al. (2008) Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J. Clin. Endocrinol. Metab., 93, 4088-4097.
30. Camp, R.L. et al. (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res., 10, 7252-7259.
31. Bavi, P. et al. (2010) Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol. Cancer, 9, 203.
32. Siraj, A.K. et al. (2011) Demethylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis. J. Clin. Endocrinol. Metab., 96, E215-E224.
33. Zhao, M. et al. (2011) Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin. Cancer Res., 17, 7248-7264.
34. Altman, J.K. et al. (2011) Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget, 2, 510-517.
35. Copp, J. et al. (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res., 69, 1821-1827.
36. Sun, S.Y. (2013) mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett., 340, 1-8.
37. Liu, Q. et al. (2013) Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res., 73, 2574-2586.
38. Pirrotta, M.T. et al. (2011) Targeted-therapy in advanced renal cell carcinoma. Curr. Med. Chem., 18, 1651-1657.
39. Prins, M.J. et al. (2013) Over-expression of phosphorylated mammalian target of rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study. J. Clin. Pathol., 66, 224-228.
40. Altman, J.K. et al. (2011) Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin. Cancer Res., 17, 4378-4388.
41. Lin, S.F. et al. (2012) Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One, 7, e46726.
42. Samovski, D. et al. (2010) Gating of the mitochondrial permeability transition pore by long chain fatty acyl analogs in vivo. J. Biol. Chem., 285, 6879-6890.
43. Hsu, Y.T. et al. (1997) Nonionic detergents induce dimerization among members of the Bcl-2 family. J. Biol. Chem., 272, 13829-13834.
44. Liu, J. et al. (2011) Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants. Mod. Pathol., 24, 1553-1559.
45. Faustino, A. et al. (2012) mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 97, E1139-E1149.
46. Hudes, G. et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 356, 2271-2281.
47. Shaw, R.J. et al. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424-430.
48. Avdulov, S. et al. (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell, 5, 553-563.
49. O'Reilly, K.E. et al. (2009) Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin. Cancer Res., 15, 2872-2878.
50. Cassinelli, G. et al. (2013) Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr. Med. Chem., 20, 1923-1945.
51. Ai, X. et al. (2011) Generation and characterization of antibodies specific for caspase-cleaved neo-epitopes: a novel approach. Cell Death Dis., 2, e205.